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Edited by Sandro SonninoAbstract Pyruvate and 2-oxoglutarate dehydrogenase com-
plexes are strongly inhibited by phytanoyl-CoA (IC50  106–
107 M). Palmitoyl-CoA is 10-fold less potent. Phytanic or
palmitic acids have no inhibitory eﬀect up to 0.3 mM. At the sub-
strate saturation, the acyl-CoA’s aﬀect the ﬁrst and second enzy-
matic components of the 2-oxoglutarate dehydrogenase complex,
while the third component is inhibited only at a low saturation
with its substrate dihydrolipoamide. Thus, key regulatory branch
points of mitochondrial metabolism are targets of a cellular
derivative of phytanic acid. Decreased activity of the complexes
might therefore contribute to neurological symptoms upon accu-
mulation of phytanic acid in Refsum disease.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Refsum disease, an inherited peroxisomal disorder with neu-
rological clinical features, is characterized by accumulation of
a saturated branched chain fatty acid, phytanic acid [1]. The
plasma concentration of phytanic acid increases in patients
up to millimolar. Molecular targets of the toxic action of phy-
tanic acid have hardly been characterized. However, in brain
mitochondria and rat hippocampal astrocytes, phytanic acid
was shown to perturb Ca2+ homeostasis, causing mitochon-
drial dysfunction with substantial generation of reactive oxy-
gen species (ROS) [2–4]. It is known that Ca2+ signaling toAbbreviations: E1o, 2-oxoglutarate dehydrogenase; E1p, pyruvate de-
hydrogenase; E2o, dihydrolipoamide succinyltransferase; E2p, dihy-
drolipoamide acetyltransferase; E3, dihydrolipoamide dehydrogenase;
OGDHC, 2-oxoglutarate dehydrogenase complex; PDHC, pyruvate
dehydrogenase complex; ROS, reactive oxygen species; ThDP, thia-
mine diphosphate
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doi:10.1016/j.febslet.2006.05.040mitochondria is mediated by the 2-oxo acid dehydrogenase
complexes [5–7] which also may be active producers of ROS
under metabolic imbalance [8,9]. The reactions catalyzed by
the complexes are key branch points of mitochondrial metab-
olism. In good accord with this, the 2-oxoglutarate dehydroge-
nase complex (OGDHC) is a point of convergence in a number
of neuropathologies, which are associated with mitochondrial
dysfunction [10]. It is also known that the complexes are inhib-
ited by acyl-CoA’s [11–20]. On the other hand, the fatty acyl-
CoA’s are usually formed upon tissue accumulation of fatty
acids [21]. In particular, CoA esters of phytanic acid are
formed in cells [22]. Hence, we suggested that the phytanic
acid-induced neurological impairment could be, in particular,
due to mitochondrial dysfunction upon inhibition of the 2-
oxo acid dehydrogenase complexes by phytanoyl-CoA.
The 2-oxo acid dehydrogenase complexes comprise multiple
copies of the three enzyme components. A multistep process
involves the cofactors thiamine diphosphate (ThDP), lipoic
acid, CoA, FAD and NAD+ and sequential action of the 2-
oxo acid dehydrogenase (E1), dihydrolipoamide acyltransfer-
ase (E2) and dihydrolipoamide dehydrogenase (E3). Splitting
the C1–C2 bond of the 2-oxo acid, the complexes preserve its
energy in the corresponding acyl-CoA’s and NADH (reactions
(1)–(5); summary (6)):
HOOC-C=O + ThDP-E1 ⎯→ CO 2 + OH-C--ThDP-E1 ⏐ ⏐
R   R 
ð1Þ
OH-C--ThDP-E1 + Lip(S-S)-E2 ↔ ThDP-E1 + O=C~S-Lip(SH)-E2 
⏐ ⏐
 R   R 
ð2Þ
O=C~S-Lip(SH)-E2 + HS-CoA ↔ O=C~S-CoA + Lip(SH)2-E2 ⏐ ⏐
  R  R 
ð3Þ
Lip(SH)2-E2 + E3(S-S)-FA D ↔ Lip(S-S)-E2 + E3(SH)2-FAD ð4Þ
E3(SH)2-FAD + NAD+ ↔ E3(S-S)-FAD + NADH + H+ ð5Þ
 HOOC-C=O + HS-CoA + NAD+ ⎯→  O=C~S-CoA + CO2 + NADH + H+⏐ ⏐
 R R 
ð6Þblished by Elsevier B.V. All rights reserved.
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oxoglutarate or branched chain 2-oxo acids is determined by
the ﬁrst (E1p, E1o, E1b) and second (E2p, E2o, E2b) compo-
nents, while the terminal E3 component is common to all the
members of the family. Acetyl- and succinyl-CoA’s are feed-
back inhibitors of the respective pyruvate and 2-oxoglutarate
dehydrogenase complexes. Their interaction with these enzy-
matic systems is described by a complex mechanism. Depend-
ing on the substrate speciﬁcity and source of the complex, it
may involve regulatory phosphorylation of E1p [11] and direct
eﬀects on E2 and/or E1 components [12–20]. The inﬂuence of
fatty acyl-CoA’s on pyruvate oxidation was widely studied
using intact cells, tissues, animals [23], and mitochondria or
mitochondrial extracts [24–26]. These studies revealed that pal-
mitoyl-CoA causes, in particular, the tissue-speciﬁc inhibition
of the pyruvate dehydrogenase complex (PDHC) due to in-
crease in its phosphorylation, which renders the pyruvate
dehydrogenase component inactive. Direct inhibitory eﬀects
of some fatty acyl-CoA’s on the pyruvate and 2-oxoglutarate
dehydrogenase complexes puriﬁed from heart were also ob-
served [12,27]. However, these observations did not allow
one to predict the sensitivity of the complexes to the branched
chain fatty acid derivatives, like phytanoyl-CoA. The present
work tested the inﬂuence of phytanic acid and its CoA deriva-
tive on the reactions catalyzed by the 2-oxo acid dehydroge-
nase complexes and their component enzymes. Our results
show that the overall production of NADH and acyl-CoA’s
is strongly inhibited by phytanoyl-CoA, with the E1 and E2
components mostly aﬀected. Palmitoyl-CoA is much less po-
tent, and phytanic acid itself does not show any comparable
inhibitory eﬀect.2. Materials and methods
2.1. Enzyme isolation
2-Oxo acid dehydrogenase complexes were puriﬁed from brains of
8–12 weeks old female rats. Animals were sacriﬁced by decapitation,
and brain mitochondria were isolated as previously described [2]. All
operations were done at 4 C. The mitochondria were suspended in a
5-fold volume of 0.05 M potassium phosphate containing 13 mM
MgCl2, 1 mM CaCl2, 1 mM DTT, 1 mM ThDP and the mammalian
protease inhibitor cocktail including leupeptine (1 lg/mL), pepstatin
A (1 lg/mL), aprotinin (10 lg/mL), Pefablock SC (0.2 mM) and ben-
zamidine (1 mM) (buﬀer A). The suspension was sonicated using re-
peated 30 s cycles at the middle power of a sonicator (Bandelin,
Berlin). 0.1 mL aliquots of the sonicated sample were centrifuged for
5 min at the maximum speed of an Eppendorf centrifuge, and appear-
ance of the E3 activity in the supernatant was used to follow the mito-
chondrial disruption. After a plateau value in the E3 activity was
achieved, the sonicated mitochondria were centrifuged for 40 min in
a High Speed Beckman centrifuge at 40000 · g. The pellet fraction
was suspended in a 5-fold volume of buﬀer A containing 1% CHAPS
and centrifuged for 40 min in a high speed Beckman RC-5 centrifuge at
40000 · g. The supernatant was adjusted to pH 6.45 with 1 M potas-
sium phosphate, pH 6.3, and the protein precipitated with 0.15 volume
of the 35% polyethylene glycol 6000. The pellet was collected by 20 min
centrifugation at 40000 · g, suspended in a minimal volume of buﬀer
A and clariﬁed by 10 min centrifugation in an Eppendorf centrifuge
at 10000 · g. The supernatant was subject to chromatography on the
Sephacryl HR400 column (Pharmacia) eluted with 0.1 M potassium
phosphate containing 1 mM MgCl2. Fractions with the highest activi-
ties of the 2-oxo acid dehydrogenase complexes were collected and
concentrated in a Millipore centrifugal device (cut oﬀ MW 10000)
according to the recommendations of the manufacturer. Preparations
obtained by this method are stable and have speciﬁc activity of
0.7 lmol/(min mg) in the 2-oxoglutarate dehydrogenase and0.06 lmol/(min mg) in the pyruvate dehydrogenase reactions. Com-
pared to the previously published procedure [28], increased stability
and at least a 3.5-fold increase in the speciﬁc activity of the partially
puriﬁed brain 2-oxoglutarate dehydrogenase complex was thus
achieved.
2.2. Enzyme assays
Activities of the 2-oxo acid dehydrogenase complexes (reaction (6))
were determined as described earlier [28]. E3 activity (reactions (4)
and (5)) was measured in 0.1 M potassium phosphate, pH 7.6, including
1 mM lipoamide, 10 mMDTT and 4 mMNAD+. E1o activity (reaction
(1) in the presence of an artiﬁcial electron acceptor) was determined in
0.05 M potassium phosphate, pH 6.3, including 2 mM 2-oxoglutarate,
1 mM MgCl2, 1 mM ThDP and 0.8 mM potassium hexacyanoferrate
(III). The reactions were started by the enzyme addition. Acyl-CoA’s
were added from a 2 mM solution in 0.02 M MES buﬀer, pH 6.0, to
the standard reaction media, if not indicated otherwise. Phytanic and
palmitic acid were added from a 20 and 100 mM solution in 96% etha-
nol, correspondingly, to the reaction medium containing 1% Triton
X-100. Control experiments showed that neither OGDHC, nor E3
activities were aﬀected by the concentrations of ethanol and detergent
present in the medium with the fatty acids.
2.3. Modeling studies
Construction of the enzyme-inhibitor complexes was done using as
templates the known X-ray structures of the catalytic domain of E2p
from Azotobacter vinelandii complexed with CoA or dihydrolipoamide
(PDB-entries 1EAD and 1EAE, respectively) [29]. The inhibitors phy-
tanoyl- and palmitoyl-CoA were modeled in a conformation, which
corresponded to the productive conformations of CoA and dihydrolip-
oamide bound to the active site of E2p. All model constructions were
done using the program SwissPDBViewer [30]. The constructed com-
plexes, after solvating them in a water shell, were subjected to an en-
ergy minimization using the program Gromacs [31] until
convergence of the energy values was reached. The homology based
modeling of the structure of the catalytic domain of E2o from rat
was done using the automated protein modeling service SwissModel
[32] and high homology between the sequences of the catalytic domains
of rat E2o and A. vinelandii E2p (60% identical residues and 20% con-
servative substitutions).
2.4. Materials
Phytanic acid was from Larodan (Sweden); phytanoyl- and palmi-
toyl-CoA’s were synthesized according to the published method [33].
Salts and CHAPS were from Roth, leupeptine, pepstatin and aprotinin
from Biomol, Pefabloc SC from Fluka, and all other reagents from
Sigma.3. Results
2-Oxo acid dehydrogenase complexes puriﬁed from brain
are strongly inhibited by phytanoyl- and palmitoyl-CoA’s
(Table 1). At a 17-fold excess of CoA, 0.003 mM phytanoyl-
CoA causes 70–80% inhibition of the overall reactions cata-
lyzed by the complexes. Under the same conditions, palmi-
toyl-CoA is signiﬁcantly less eﬃcient, not inhibiting
OGDHC and providing only about 30% inhibition of the
PDHC.
Fig. 1 shows the dependence of the inhibition on the concen-
tration of acyl-CoA’s and CoA. At a ﬁxed acyl-CoA concen-
tration, the inhibition increases with decreasing saturation of
the complexes with CoA. However, the CoA dependence of
the inhibition is observed only within a certain interval of the
acyl-CoA concentrations (below 0.006 mM palmitoyl-CoA,
Fig. 1). At higher acyl-CoA concentrations, the inhibition does
not depend on the CoA concentration. In particular, it cannot
be reversed by increasing the amount of CoA. That is,
OGDHC inhibited by 0.001 mM phytanoyl-CoA at 0.01 mM
Table 1
Inhibition of brain 2-oxo acid dehydrogenase complexes by phytanoyl-
and palmitoyl-CoA’s
Conditions PDHC activity (%) OGDHC activity (%)
Control 100 ± 12 100 ± 5
Phytanoyl-CoA 28 ± 5 17 ± 3
Palmitoyl-CoA 72 ± 9 95 ± 3
The reaction was measured at 0.003 mM acyl-CoA’s and full satura-
tion with the substrates of the overall reaction (in particular, at CoA of
0.05 mM), as described in Section 2.
Acyl-CoA, uM



















Phytanoyl-CoA, CoA 8 uM
Palmitoyl-CoA, CoA 8 uM
Palmitoyl-CoA, CoA 2 uM
Fig. 1. Inhibition of brain 2-oxoglutarate dehydrogenase complex by
phytanoyl- and palmitoyl-CoA’s at diﬀerent concentrations of CoA.
Activity of the complex was assayed under CoA concentrations
indicated in the ﬁgure and saturation with all other substrates and
cofactors as described in Section 2. Initial reaction rate was determined
after starting the reaction by enzyme.
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with CoA up to 0.6 mM. Thus, the inhibition by the acyl-
CoA’s is partly competitive with respect to CoA, but the
competition for the CoA-binding site on the E2 component
of the complexes does not fully describe the inhibition process.
A complex mechanism of the inhibition was conﬁrmed in
further studies on the inﬂuence of the acyl-CoA’s on the par-
ticular enzymatic activities of the multienzyme complexes. Ta-
ble 2 shows that the ﬁrst component of OGDHC, E1o, is
strongly inhibited by the acyl-CoA’s in a concentration-depen-
dent manner. The strong inhibitory eﬀect is observed under
saturation with 2-oxoglutarate and an artiﬁcial electron accep-
tor. Similar to other allosteric regulators of E1o [34,35], the
acyl-CoA’s aﬀected the initial rates of the E1o catalysis much
more than the steady-state rates. The E3 component is not
inhibited by the acyl-CoA’s at saturating concentration ofTable 2
Residual activities (%) of E1o and E3 in the presence of phytanoyl- and pal
Component Phytanoyl-CoA (mM)
0 0.003 0.006
E1o 100 ± 10 33 ± 6 0
E3 100 ± 7 104 ± 8 –
Initial reaction rates of E1o and E3 were determined at saturating substratedihydrolipoamide and NAD+. Decreasing the dihydrolipoam-
ide concentration down to 0.1 and 0.05 mM gives about 30%
and 50% inhibition by 0.03 mM palmitoyl-CoA, respectively.
However, the low concentration (0.003 mM) of palmitoyl- or
phytanoyl-CoA does not inhibit E3 even at a low saturation
with dihydrolipoamide. Thus, under conditions of strong inhi-
bition of the overall reaction by the acyl-CoA’s (Table 1), both
E1o (Table 2) and the CoA-binding site of E2o (Fig. 1) are in-
volved, while the E3 component does not contribute to the
inhibition.
Phytanic acid (0.03 and 0.3 mM) or palmitic acid (0.3 mM)
inhibit OGDHC neither in the standard reaction medium,
nor at a low CoA concentration (0.01 mM). Hence, activation
of the fatty acids to the corresponding acyl-CoA’s is essential
for the inhibition to occur.
In view of our results suggesting the fatty acyl-CoA binding
to the E2 active site, we modeled this interaction using the
known structures of the binary complexes between A. vinelan-
dii E2p and CoA or dihydrolipoamide [29]. Fig. 2A shows the
superposition of the molecule of phytanoyl-CoA onto CoA
and dihydrolipoamide in their productive conformations at
the active site channel of E2p. Taking into account that the
E2p active site binds the lipoyllysine residue instead of solely
lipoamide used in the crystallographic studies, the extension
of the phytanoyl residue over dihydrolipoamide, as seen in
Fig. 2A, would ﬁt the space for the lysine residue of the nat-
ural ligand. The modeling showed that the E2p active site
channel may be occupied by the fatty acyl-CoA’s in such a
way that the inhibitor strongly mimicks the conformation of
the protein substrates, CoA and dihydrolipoamide. Moreover,
additional van der Waals interactions may be formed between
the hydrophobic residues of the E2p channel (Ile420 and
Leu425) with the methyl groups of the phytanoyl residue, as
compared to the palmitoyl residue (data not shown). This is
in good accord with the higher inhibitory power of phyta-
noyl- compared to palmitoyl-CoA (Table 1, Fig. 1). High
homology of the transacylases forming the cores of the 2-
oxo acid dehydrogenase complexes [36] and, in particular,
the strict conservation of their active site residues [29] enabled
us to perform homology modeling of rat E2o and its com-
plexes with the fatty acyl-CoA’s. Fig. 2B shows the complex
of the rat E2o and phytanoyl-CoA. Conformations of the
fatty acyl-CoA’s in E2p (Fig. 2A) and E2o (Fig. 2B) are
highly similar. Also in E2o some extra van der Waals interac-
tions may be formed with phytanoyl- vs palmitoyl-CoA
through Ile235 and Leu239 residues of the active site channel
(Fig. 2B). The results suggest that the observed tight binding
of the fatty acyl-CoA’s to the 2-oxo acid dehydrogenase com-
plexes (IC50  106–107 M) may be due to the transition
state analogue properties of the complexes between the fatty
acyl-CoA’s and the E2 components of the 2-oxo acid dehy-
drogenase complexes.mitoyl-CoA’s
Palmitoyl-CoA (mM)
0 0.003 0.006 0.03
100 ± 10 – 55 ± 6 38 ± 5
100 ± 7 102 ± 8 – 98 ± 7
concentrations, as described in Section 2.
Fig. 2. Modeling of the binding of phytanoyl-CoA to the E2 active
sites. The pdb ﬁles 1EAD und 1EAE [29] were used for the modeling.
Heteroatoms of phytanoyl-CoA are coloured: red for oxygen, blue for
nitrogen, green for phosphorus and yellow for sulfur. (A) Superpo-
sition of phytanoyl-CoA (grey) onto the relative orientations of CoA
(turquoise) and dihydrolipoamide (lilac) at the Azotobacter vinelandii
E2p active site; (B) modeled binding of phytanoyl-CoA to the active
site channel of rat E2o. See text for further details.
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This work has shown that key systems of central metabo-
lism, the mitochondrial pyruvate and 2-oxoglutarate dehydro-
genase complexes are strongly and speciﬁcally inhibited by
phytanoyl-CoA. This observation has biological implications
regarding the neurotoxic eﬀects of phytanic acid which is accu-
mulated in Refsum disease. As pointed out by Cooper and
coworkers [27], once the fatty acids enter the tissues and cells,
they are metabolically converted to CoA derivatives. Taking
into account that Refsum disease is characterized by the plas-
ma accumulation of phytanic acid, on the one hand, and neu-
rological symptoms, on the other hand, our data on the
phytanoyl-CoA inhibition of the 2-oxo acid dehydrogenase
complexes are in good agreement with observations by severalindependent laboratories reporting that reduced activity of
OGDHC is associated with neurodegeneration [10].
OGDHC may limit energy production in the tricarboxylic
acid cycle [37] and is directly involved in the function of gluta-
mate as neurotransmitter, since 2-oxoglutarate is generated
both in the cycle and from glutamate transamination. PDHC
couples anaerobic and aerobic glucose oxidation and is essen-
tial for the acetylcholine neurotransmitter function, because it
provides acetyl-CoA to the tricarboxylic acid cycle and acetyl-
choline synthesis. Thus, decrease in both energy and acetylcho-
line production and elevation in glutamate may link the
inhibition of the complexes by phytanoyl-CoA with neurolog-
ical symptoms. The inhibition of the physiological reaction of
the complexes should impair the Ca2+ signaling to mitochon-
dria [7] and may stimulate the non-physiological side reactions
such as ROS production [8,9]. This is consistent with the per-
turbed Ca2+ homeostasis and increased ROS generation upon
incubation of neural cells with phytanic acid [2–4].
We can distinguish several components of the inhibition of the
complexes by the fatty acyl-CoA’s. At low concentrations of the
acyl-CoA’s, CoA partially protects OGDHC from the inhibi-
tion (Fig. 1). The dependence of the inhibition of the overall
reaction on CoA suggests a competition between the fatty
acyl-CoA’s and CoA at the active site of E2. This result is in
accord with earlier data [12], when amodel reaction withDTNB
was used to assess speciﬁcally the E2o activity. Erﬂe and Sauer
showed palmitoyl-CoA to compete for the CoA/succinyl-CoA
binding site on E2. In addition, the feedback eﬀectors acetyl-
and succinyl-CoA’s exert their inhibitory eﬀects through compe-
tition with CoA at the E2 active sites [12,16–18]. Remarkably,
E2may transfer the short chain acyls from their CoAderivatives
to dihydrolipoamide, but this reaction is impossible with palmi-
toyl-CoA [12]. Our modeling provides a good explanation for
this diﬀerence. Similar to the phytanoyl-CoA shown in Fig. 2,
palmitoyl-CoA bound at the E2 active site would occupy the
dihydrolipoamide binding site, thus blocking the transacylation
reaction.When the short-chain acyl-CoA’s are bound, the active
site channel is able to accommodate dihydrolipoamide, and the
transacylation may take place.
The competition at the CoA-binding site cannot fully ex-
plain the inhibition of the 2-oxo acid dehydrogenase complexes
by phytanoyl- and palmitoyl-CoA’s. The following ﬁndings
point to additional inhibitory mechanisms involved. (i) There
is no signiﬁcant reversal of the inhibition at a high excess of
CoA. (ii) The same level of inhibition is achieved at both
low and high saturation with CoA upon an increase in the
fatty acyl-CoA concentration. (iii) The fatty acyl-CoA’s inhibit
the ﬁrst component as well. The observations (i) and (ii) indi-
cate that the reversible formation of the E2-inhibitor complex
is followed by an irreversible (under conditions of experiment)
step, with CoA competing on the reversible stage (reaction
(7)):
E2þ I$ E2-I! E2-I ð7Þ
Formation of a tightly-bound transition state analogue at
the E2 active site, as suggested by Fig. 2, would be in good ac-
cord with reaction (7). Obviously, CoA may compete with the
inhibitor at the reversible stage, but not during the (quasi)-irre-
versible transformation into the E2-I* complex. Fig. 1 shows
that the dependence of the inhibition on the acyl-CoA concen-
tration is indeed not described by a single fast equilibrium be-
tween the active and inactive enzyme species, as would be
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the activity upon an increase in the concentration of fatty
acyl-CoA’s is slow, but the maximal inhibition is further
achieved within a relatively small concentration interval. Sev-
eral factors may contribute to this. First, in our experiments
the initial reaction rates were measured without preincubation
of the enzyme with the inhibitor. These conditions allowed us
to see the competition with CoA. When the enzyme was prein-
cubated with the inhibitor [12], the competition with CoA in
the overall reaction was not observed, obviously due to the
high stability and rapid formation of E2-I*. While the equilib-
rium between E2, CoA and acyl-CoA is achieved within the
pre-steady state (ms), the time needed for the irreversible step
appears to be comparable to the dead time of the registration
(s). Owing to this, at low inhibitor concentrations the mea-
sured activity rather depends on E2-I (and CoA), while at high
inhibitor concentrations – on the ﬁnal E2-I*. This should lead
to the deviation from the single equilibrium kinetics as ob-
served in Fig. 1. Second, the decay in the overall reaction rate,
similar to that in Fig. 1, was already observed before upon dif-
ferent types of the E2 inactivation [38,39]. It was shown that as
far as the overall reaction (6) is concerned, the E2 inactivation
may be tolerated to a certain degree, due to the multiple ran-
dom coupling mechanism between the catalytic sites within
the 2-oxo acid dehydrogenase complexes. Finally, the con-
certed action of the fatty acyl-CoA’s on both the ﬁrst (Table
2) and second (Fig. 1) components, which strongly interact
functionally and structurally, may also contribute to the higher
order of the concentration dependence presented in Fig. 1.
Another factor which should be taken into account upon
studying the inhibition by fatty acyl-CoA’s is their propensity
to micellize in solution. At those concentrations where fatty
acyl-CoA’s form micelles, the detergent properties of the
compounds may cause enzyme dissociation resulting in inhi-
bition. However, according to diﬀerent authors having used
a number of approaches [40,41], the critical micellar concen-
tration for palmitoyl-CoA under conditions similar to ours
(0.05 M potassium phosphate, pH 7.4, vs 0.05 or 0.1 M
potassium phosphate, pH 6.3, 7.0 or 7.6 in our experiments)
is in the range from 30 to 80 lM. As Fig. 1 and Table 2 show,
70% of OGDHC and 50% of E1o activities are inhibited by
12 and 6 lM palmitoyl-CoA, respectively, i.e. far below the
concentration where micelles are formed. These data are in
good accord with the earlier ﬁnding that inhibition of the
2-oxoglutarate dehydrogenase complex by palmitoyl-CoA
does not coincide with dissociation of the complex [12].
Besides, the OGDHC or E3 inhibition by palmitoyl-CoA de-
pend on saturation with their substrates CoA or dihydrolipo-
amide. The competition with CoA (Fig. 1) is supported by
our modeling studies (Fig. 2), providing further evidence for
the existence of a speciﬁc site for the fatty acyl-CoA’s on
E2’s. The critical micellar concentration of phytanoyl-CoA
is unknown. Nevertheless, the same mechanisms of inhibitory
action of phytanoyl- and palmitoyl-CoA’s are to be expected.
That is, the higher eﬃciency of phytanoyl-CoA (Fig. 1,
Tables 1 and 2) inhibiting already at 0.5–1 lM is unlikely
to be due to unspeciﬁc eﬀects such as micelle formation and
dissociation of OGDHC or PDHC. On the contrary, this
can be well explained by a stronger binding at the E2p and
E2o active sites due to additional hydrophobic interactions
of the branched chain fatty acyl-CoA’s with the Ile and
Leu residues (Fig. 2).Based on earlier studies [23,26], one may suggest that the
phytanoyl-CoA inhibition of the PDHC could also be medi-
ated by the E1p kinase/phosphatase regulatory system. How-
ever, the possible inﬂuence of phytanoyl-CoA on this system
was beyond the scope of the present study. In contrast to
the eukaryotic PDHC for which the sensitivity to acetyl-
CoA/CoA, NADH/NAD+ and ATP/ADP ratios is mediated
by phosphorylation, OGDHC responds to changes in these ra-
tios directly. The lower susceptibility of OGDHC to palmi-
toyl-CoA as compared to PDHC (Table 1) may reﬂect the
cellular need of having the OGDHC-catalyzed process
switched on also when palmitoyl-CoA is increased and PDHC
is switched oﬀ. The structural features of OGDHC, which
could evolve to decrease inhibition by palmitoyl-CoA, proba-
bly brought about a concomitant increase in susceptibility
to phytanoyl-CoA which is not a normal metabolite of
mitochondria.
We conclude that the inhibition of the 2-oxo acid dehydro-
genase complexes by fatty acyl-CoA’s involves binding to the
second component of the complexes and allosteric inhibition
of the ﬁrst component. Although E3 does not contribute to
the inhibition of the overall reaction (Tables 1 and 2), we
showed that it still may interact with the fatty acyl-CoA’s un-
der low saturation with dihydrolipoamide. This is not relevant
for oxidative decarboxylation of the 2-oxo acids (reaction (6)),
because under conditions of the E3 inhibition reaction (6)
would already be inhibited due to much higher sensitivity to
the acyl-CoA’s of E2 and E1. However, binding of the fatty
acyl-CoA’s to E3 may aﬀect catalytic activities of E3 beyond
those described by reactions (4) and (5). It is known that some
of the E3-catalyzed ‘‘non-physiological’’ reactions including
the ROS production may be stimulated when the physiological
process is blocked (reviewed in [9,10]). Taking into account the
well-known pathophysiological signiﬁcance of the ROS pro-
duction and increased ROS generation upon incubation of
neural cells with phytanic acid [2–4], the inﬂuence of the E3
interaction with phytanoyl-CoA on the non-physiological
activities of E3 deserves further investigation.
The degree of inhibition of the pyruvate and 2-oxoglutarate
dehydrogenase complexes, which occurs in vivo, still remains
to be established. Obviously, the inhibition would depend on
the presence of phytanoyl-CoA in the mitochondrial matrix.
Like other cellular compartments, such as cytoplasm, peroxi-
somes and microsomes, mitochondria are able to synthesize
phytanoyl-CoA [42], but it is still unclear whether phytanic
acid reaches the mitochondrial matrix. The known pathway
of transport for long chain fatty acids into mitochondria in-
cludes their transformation into acyl-CoA’s. The latter are syn-
thesized in the cytoplasm and traverse the mitochondrial
membrane through the acylcarnitine pathway. However, there
is no information in the literature, whether this pathway func-
tions for phytanoyl-CoA. If this is not the case, then, under the
permanent increase in phytanic acid concentration, the activity
of cytoplasmatic fatty acyl-CoA synthetase should be reduced
by the product and/or exhaustion of the cytoplasmic pool of
free CoA. This should lead to accumulation of free phytanic
acid in the cytoplasm, its passive transport into mitochondria,
and mitochondrial synthesis of phytanoyl-CoA. Whatever the
mechanism of the phytanoyl residue entrance into the mito-
chondrial matrix, chemical gradients upon accumulation of
phytanic acid in Refsum disease and the mitochondrial phyta-
noyl-CoA synthetase activity [42] favor the phytanoyl-CoA
3556 V.I. Bunik et al. / FEBS Letters 580 (2006) 3551–3557interaction with the 2-oxo acid dehydrogenase complexes
in vivo.
Unraveling speciﬁc lipid-dependent regulation of metabolic
systems and their components in brain is of special interest
from both the fundamental and medical points of view. This
emphasizes the signiﬁcance of further structural characteriza-
tion of the fatty acyl-CoA binding sites of the brain 2-oxo acid
dehydrogenase complexes.
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